What is Hillstream BioPharma, Inc. (HILS)?

Hillstream BioPharma, Inc. (HILS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of HILS?

The current price of HILS is $0.24. Prices are updated in real time on Stocks360.

What is HILS's price-to-earnings (PE) ratio?

HILS's trailing twelve-month PE ratio is -0.16, based on current price and earnings per share data available on Stocks360.

What is HILS's market capitalization?

HILS's market capitalization is $4,171,840.00, placing it in the small-cap tier.

Hillstream BioPharma, Inc. (HILS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.24

Market Cap

$4.17M

PE (TTM)

-0.16

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.00

Day Range

$0.22 – $0.24

52-wk Range

$0.17 – $2.65

Avg Volume

N/A

Volume

313.19K

Hillstream BioPharma, Inc. (HILS) is a publicly traded company in the Healthcare sector. Latest price: $0.24. Market cap $4.17M. Trailing PE -0.16. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 13, 2023

EPS $-0.11 vs est. $-0.05

Missed by $0.06

Proprietary Signals

Signal snapshot temporarily unavailable.

About Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.16×
P/S (TTM)	2.79×
P/B	0.11×
P/FCF (TTM)	0.11×
EV / EBITDA	0.62×
EV / Sales	-22.11×
Earnings Yield	-190.90%
Free Cash Flow Yield	889.32%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$33.07M
Net Income (TTM)	-$7.96M
Free Cash Flow (TTM)	$37.11M
Net Debt	-$37.24M
Working Capital	$38.59M
Gross Margin	0.00%
Operating Margin	-3595.17%
Net Margin	-6559.27%
Return on Equity	-29.54%
Return on Invested Capital	-8.14%